Trump's Tariff Threat Could Trigger US Generic Drug Shortages, Hitting Pharma Stocks
Trump’s tariff threat on pharmaceutical imports raises fears of generic drug shortages, hitting pharma stocks and potentially strengthening the US dollar amid…
Trump’s tariff threat on pharmaceutical imports raises fears of generic drug shortages, hitting pharma stocks and potentially strengthening the US dollar amid…
Galderma shares sank after the FDA rejected its Botox rival Relfydess, delaying U.S. market entry and strengthening AbbVie's grip on the aesthetics…
UniQure stock pops following FDA’s reversal allowing Huntington’s disease therapy AMT-130 to move toward US approval filing.
FDA Commissioner Marty Makary’s resignation throws the agency into turmoil, threatening drug approvals and pressuring biotech and healthcare stocks.
FDA gridlock clouds drug approval timelines, pressuring healthcare stocks and ETFs like XLV and IBB.